ALL ORDERS MUST BE SIGNED, DATED AND TIMED BY PHYSICIAN				
Allergies/Reactions:	Puyallup Infusion Center - Fax: 2			on Services - Fax: 253-530-8069
	Allenmore Infusion Services - Fa	x: 253-864-4052	DHEC Infusion Ce	nter - Fax: 509-755-5845
	Auburn Infusion Services - Fax: 2			fusion Center - Fax: 509-232-2531
ORDERS WITH CHECK BOXES When	an order is optional (those with ext to the order. Orders left unch	n check boxes), physicians	are responsible for	indicating a check mark in the
Risankizumab (Skyrizi)				
Patient Name:Requested Date of Service:/				
Date of Birth: / /	Patient Phone Number: (_)		🗅 May leave message
		ICD -10 Code:		
Diagnosis: Crohn's Disease		•		
Required: H&P with documentation to support above diagnosis including ICD-10 code and supporting labs and documentation. **If required documentation not received with order, scheduling of treatment will be delayed until complete information is available** Baseline labs required:				
CBC, CMP	/ Decultor			
Latent TB testing, Date:/ HBV screening Date:/				
 HBV screening, Date: / Results: HCV screening, Date: / Results: 				
 HIV screening, Date: / Results: 				
*Patients should be up to date with all immunizations before initiating therapy. Avoid the use of live vaccines in patients undergoing Risankizumab treatment				
IV Access: Access and/or maintain IV site in accordance with MHS IV Therapy P&P: Peripheral IV Device Site Selection, Insertion, Maintenance, and Discontinuation; and Maintenance of Central Venous Catheters-Flushing, Dressing Changes and Removal.				
 Risankizumab (Skyrizi) 600 mg IV infusion over 1 hour at week 0, 4 and 8 Risankizumab (Skyrizi) 360 mg SUBQ at week 12 then every 8 weeks thereafter **Medicare will not cover SUBQ in outpatient setting Vital Signs: Check vital signs prior to and at compeltion of infusion. Contact provider if systolic BP >180; diastolic BP >100; systolic BP<90; HR >110; temp >38C (100.4F) 				
 If hypersensitivity develops (fever, chills, hypotension, rigors, itching, rash, etc.): Consult MultiCare hypersensitivity guideline for treatment management Notify provider of reaction, assessment and need for futher orders 				
Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.				
Was consent obtained: 🗆 Yes 🕒 No (if yes, please send DOCUMENTATION of consent with order)				
Provider Signature	Print Name		Date	Time
			Orde	er expires in 12 months**
Patient Identification - Always Attach Patier	nt Label	Pre-printed O	rder	
Name:		CROHN'S E		
MRN #:				
CSN #:		MultiCare	/ 3	
Age / Sex and Gender:				60-0191-6 (9/22)